Ashbury Fredrick D, Thompson Keith, Williams Casey, Williams Kirstin
VieCure, Denver, Colorado, USA.
Department of Oncology, University of Calgary, Calgary, Alberta.
Curr Opin Oncol. 2021 Sep 1;33(5):507-512. doi: 10.1097/CCO.0000000000000764.
We are in an exhilarating time in which innovations exist to help reduce the impact of cancer for individuals, practitioners and society. Innovative tools in cancer genomics can optimize decision-making concerning appropriate drugs (alone or in combination) to cure or prolong life. The genomic characterization of tumours can also give direction to the development of novel drugs. Next-generation tumour sequencing is increasingly becoming an essential part of clinical decision-making, and, as such, will require appropriate coordination for effective adoption and delivery.
There are several challenges that will need to be addressed if we are to facilitate cancer genomics as part of routine community oncology practice. Recent research into this novel testing paradigm has demonstrated the barriers are at the individual level, while others are at the institution and societal levels.
This article, based on the authors' experience in community oncology practice and summary of literature, describes these challenges so strategies can be developed to address these challenges to improve patient outcomes.
我们正处于一个令人振奋的时代，存在诸多创新手段来帮助减轻癌症对个人、从业者和社会的影响。癌症基因组学中的创新工具能够优化关于合适药物（单独使用或联合使用）以治愈或延长生命的决策。肿瘤的基因组特征还可为新型药物的研发提供方向。新一代肿瘤测序正日益成为临床决策的重要组成部分，因此，需要进行适当协调以有效采用和实施。
如果要将癌症基因组学作为常规社区肿瘤学实践的一部分加以推广，就需要应对若干挑战。近期对这种新型检测模式的研究表明，有些障碍存在于个体层面，而其他障碍则存在于机构和社会层面。
本文基于作者在社区肿瘤学实践中的经验以及文献综述，描述了这些挑战，以便能够制定策略来应对这些挑战，从而改善患者预后。
